Skip to content

Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF

Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF - ATTAC CFAE Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01229033
Acronym
ATTAC CFAE
Enrollment
186
Registered
2010-10-27
Start date
2010-01-31
Completion date
2014-01-31
Last updated
2017-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Ablation, Atrial Flutter

Keywords

Atrial fibrillation, ablation, atrial flutter

Brief summary

Catheter ablation has proven to be an effective treatment option in patients suffering from symptomatic persistent atrial fibrillation (AF). Catheter ablation consists of two major steps: (1) Isolation of pulmonary veins to abolish the trigger of atrial fibrillation and (2) modification of left atrial and eventually right atrial substrate by ablation of complex fractionated atrial electrograms (CFAE). CFAE are mainly found at the ostia of the pulmonary veins, around the left atrial appendage, at the mitral annulus and the septum. When ablating CFAE 40-65% of the patients show a regularization of AF to an atrial tachycardia (AT) that can be macro- or micro-reentrant (localized re-entry). Until now the significance of the AT is unclear. In the following study we examine the hypothesis that an ablation of AT occuring during CFAE ablation (group 1) significantly improves outcome defined as freedom of atrial arrhythmia (AF or AT) compared to patients that are cardioverted when AF has regularized to AT (group 2).

Interventions

PROCEDUREAblation

Ablation of atrial tachycardia

PROCEDURECardioversion

Cardioversion of atrial tachycardia

Sponsors

Klinik für Kardiologie, Klinikum Karlsruhe, Prof. Dr. C. Schmitt
CollaboratorUNKNOWN
Deutsches Herzzentrum Muenchen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients (\>=18 und \< 80 years) with symptomatic persistent AF (AF episode enduring at least 7 days) but are successfully convertable in sinus rhythm (SR). * At least one unsuccessful attempt of antiarrhythmic drug (betablocker or class I oder III). * Oral anticoagulation with phenprocoumone or warfarine for at least 4 weeks prior to ablation with weekly documented INR \> 2.. * Withdrawal of antiarrhythmic drugs at least 3 half times prior to ablation except amiodarone. * Atrial tachycardia occurring during ablation of CFAE (defined as CL \> 200 msec und stable activation sequence).

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Freedom from atrial tachyarrhythmiaDocumented freedom from atrial tachyarrhythmia (AF or AT) during follow-up after first ablation.

Secondary

MeasureTime frameDescription
Procedural and safety data1. Duration of left atrial procedure, time of ablation, time of radiation and radiation dose from randomization until the end of the procedure. 2. In case of recurrence, characteristic of predominant tachyarrhythmia (AF or AT). 3. Safety parameters (pericardial tamponade, thrombembolic complications). 4. Number of re-ablations.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026